脓毒性休克血流动力学复苏试验二十五年:概念视角
早期以早期目标导向治疗为代表,通过程序化干预纠正全局氧代谢指标,但后续多中心试验未能重复其获益。此后研究纳入外周灌注评估、液体反应性系统评价、重症超声和血流动力学表型分析。ANDROMEDA-SHOCK将注意力转向毛细血管再充盈时间作为快速反应的临床灌注信号,有助于改善部分结局并可能限制过度复苏;ANDROMEDA-SHOCK-2进一步将基于毛细血管再充盈时间、序贯表型分析、可逆血流动力学试验和连续再评估的个体化策略操作化。结论支持从孤立血流动力学或代谢目标转向生理引导、表型驱动的复苏策略。
要点
- 以固定孤立生理目标为中心的程序化复苏策略(如早期目标导向治疗)在后续多中心试验中未能重复改善以患者为中心的结局。
- ANDROMEDA-SHOCK将毛细血管再充盈时间作为快速反应的临床灌注信号,有助于改善部分结局并可能限制过度复苏。
- ANDROMEDA-SHOCK-2将基于毛细血管再充盈时间、序贯表型分析、可逆血流动力学试验和连续再评估的个体化策略进一步操作化。
- 当前方向是将干预作为可逆试验在短决策周期内应用,并由快速反应的灌注信号引导,而非依赖孤立终点。
- 该策略仍需进一步细化、验证并在不同环境中实施。
适用人群与场景
- 脓毒性休克患者,处于早期血流动力学复苏阶段。
- 原文未明确列出纳入或排除的具体人群标准。
诊断标准与关键阈值
- 原文未提及具体的诊断标准名称、评分界值或启动/停止阈值。
- 文中提及以毛细血管再充盈时间作为快速反应的临床灌注信号,但未给出具体界值。
处置流程与药物剂量
- 第一步:进行个体化生理评估,包括外周灌注评估、液体反应性系统评价、重症超声和血流动力学表型分析。
- 第二步:以毛细血管再充盈时间等快速反应灌注信号引导复苏,并可能限制过度复苏。
- 第三步:序贯表型分析,将干预作为可逆血流动力学试验在短决策周期内应用,并进行连续再评估。
- 原文未提及具体药物名称、剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:概念视角文章,非系统评价或原始研究。
- 早期目标导向治疗通过程序化干预优化氧输送以纠正全局氧代谢指标,但后续多中心试验未能重复其获益。
- ANDROMEDA-SHOCK将注意力转向毛细血管再充盈时间,有助于改善部分结局并可能限制过度复苏。
- ANDROMEDA-SHOCK-2进一步操作化了基于毛细血管再充盈时间、序贯表型分析、可逆血流动力学试验和连续再评估的个体化策略。
证据类型、等级与局限
- 证据类型:概念视角文章(综述/专家意见),非RCT或系统评价。
- 局限:作者指出该策略仍需进一步细化、验证并在不同环境中实施。
对床旁实践的改变
- 可改变的做法:不再依赖固定孤立的生理目标(如早期目标导向治疗的程序化指标)进行复苏,转向以毛细血管再充盈时间等快速反应灌注信号引导的个体化策略。
- 可改变的做法:将液体反应性评估、重症超声和血流动力学表型分析纳入早期复苏决策,干预作为可逆试验在短决策周期内应用并连续再评估。
- 适用人群:脓毒性休克早期复苏患者;原文未明确不适用人群。
- 常见陷阱:基于孤立终点的刚性算法在后续多中心试验中未能重复改善结局;需避免过度复苏。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Twenty-five years of septic shock resuscitation trials have progressively transformed the physiological understanding of shock and the way bedside interventions are conceptualized. Early strategies focused on correcting isolated global hemodynamic or metabolic targets through protocolized interventions, whereas more recent approaches increasingly recognize septic shock as a heterogeneous, dynamic, and context-dependent condition requiring individualized physiological assessment.
MAIN BODY: This perspective discusses how hemodynamic resuscitation trials during this quarter of a century have reshaped both the physiological understanding and methodological foundations of early shock management. Initial strategies, exemplified by early goal-directed therapy, aimed to correct global oxygen-derived variables through protocolized interventions designed to optimize oxygen delivery. However, the lack of reproducibility of this approach in subsequent multicenter trials, together with the recognition of the limitations of several other variables as potential resuscitation targets, revealed that septic shock cannot be adequately addressed through rigid algorithms based on isolated endpoints. Subsequent progress incorporated peripheral perfusion assessment, systematic evaluation of fluid responsiveness, critical care echocardiography, and hemodynamic phenotyping. Within this trajectory, ANDROMEDA-SHOCK shifted attention toward capillary refill time as a rapidly responsive clinical perfusion signal, contributing to improve some outcomes, and potentially limiting over-resuscitation. ANDROMEDA-SHOCK-2 further operationalized a personalized strategy based on capillary refill time, sequential phenotyping, reversible hemodynamic tests, and serial reassessment.
CONCLUSIONS: A quarter of a century of septic shock resuscitation trials reveal a consistent pattern: strategies centered on fixed and isolated physiological targets have repeatedly failed to achieve reproducible improvements in patient-centered outcomes. Recent data support a shift from isolated hemodynamic or metabolic targets, toward a physiology-guided, phenotype-driven resuscitation strategy, in which interventions are applied as reversible tests within short decision cycles and guided by rapidly responsive perfusion signals. Trials such as ANDROMEDA-SHOCK-2 represent important steps in this ongoing transition, but further refinement, validation, and implementation across diverse settings remain necessary.
参考来源
- Hernandez G, Hunsicker O, de Backer D, et al. Twenty-five years of septic shock hemodynamic resuscitation trials: a conceptual perspective. Crit Care. 2026. PMID: 42482139. doi:10.1186/s13054-026-06201-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。